Should We Systematically Screen for the Amyloidogenic V142I Variant?

Regan, Jessica A; Khouri, Michel G; Olabisi, Opeyemi A; Alexander, Kevin M; Khan, Sadiya S; Shah, Svati H; Selvaraj, Senthil

Regan, Jessica A; Khouri, Michel G; Olabisi, Opeyemi A; Alexander, Kevin M; Khan, Sadiya S; Shah, Svati H; Selvaraj, Senthil.

Affiliation

Regan JA; Division of Cardiology, Duke University School of Medicine, Durham, NC; Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC.
Khouri MG; Division of Cardiology, Duke University School of Medicine, Durham, NC.
Olabisi OA; Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC; Division of Nephrology, Duke University Hospital, Durham, NC.
Alexander KM; Division of Cardiovascular Medicine, Stanford University, Stanford University School of Medicine, Stanford, CA.
Khan SS; Department of Medicine (Cardiology), Northwestern University Feinberg School of Medicine, Chicago, IL; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
Shah SH; Division of Cardiology, Duke University School of Medicine, Durham, NC; Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC; Duke Center for Precision Health, Duke University School of Medicine, Durham NC.
Selvaraj S; Division of Cardiology, Duke University School of Medicine, Durham, NC; Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC. Electronic address: senthil.selvaraj@duke.edu.

J Card Fail ; 2024 Sep 19.

Article in En | MEDLINE | ID: mdl-39306232

Key words

Amyloidosis; V142I; transthyretin

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Card Fail Journal subject: CARDIOLOGIA Year: 2024 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google